Pierre-RÃ©gis Burgel

List of Publications by Year
in descending order

166 papers	7,662 citations	53794 45 h-index	60623 81 g-index
176 all docs	176 docs citations	176 times ranked	9700 citing authors

#	Article	IF	Citations
1	Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2011, 208, 1635-1648.	8.5	739
2	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
3	Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects. Chest, 2009, 135, 975-982.	0.8	299
4	Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015, 46, 133-141.	6.7	238
5	Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L165-L172.	2.9	230
6	IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L134-L140.	2.9	217
7	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	5.6	166
8	High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874.	3.2	164
9	Rapid Improvement after Starting Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	5.6	139
10	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	6.7	138
11	Human Eosinophils Induce Mucin Production in Airway Epithelial Cells Via Epidermal Growth Factor Receptor Activation. Journal of Immunology, 2001, 167, 5948-5954.	0.8	132
12	A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax, 2007, 62, 153-161.	5.6	125
13	Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Medical Mycology, 2010, 48, S32-S36.	0.7	114
14	Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36.	10.7	114
15	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358.	0.7	113
16	One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 158-164.	5.6	112
17	Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nature Communications, 2014, 5, 5105.	12.8	110
18	Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality. PLoS ONE, 2012, 7, e51048.	2.5	104

#	Article	IF	Citations
19	Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 497-503.	0.7	103
20	Impact of comorbidities on COPD-specific health-related quality of life. Respiratory Medicine, 2013, 107, 233-241.	2.9	103
21	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. European Respiratory Journal, 2016, 47, 420-428.	6.7	102
22	Artificial intelligence outperforms pulmonologists in the interpretation ofÂpulmonary function tests. European Respiratory Journal, 2019, 53, 1801660.	6.7	102
23	Real-Life Safety and Effectiveness of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	5.6	95
24	Cystic Fibrosis Transmembrane Conductance Regulator Channel Dysfunction in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1078-1084.	5.6	85
25	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	7.1	82
26	Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. Journal of Cystic Fibrosis, 2017, 16, 388-391.	0.7	81
27	Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. International Journal of COPD, 2017, Volume 12, 1819-1824.	2.3	81
28	Exacerbations of COPD. International Journal of COPD, 2016, 11 Spec Iss, 21.	2.3	79
29	Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia. Thorax, 2017, 72, 154-160.	5.6	77
30	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. Journal of Cystic Fibrosis, 2016, 15, 204-212.	0.7	76
31	The role of epidermal growth factor in mucus production. Current Opinion in Pharmacology, 2001, 1, 254-258.	3.5	74
32	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.7	74
33	Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1663.	2.3	70
34	Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps. Journal of Allergy and Clinical Immunology, 2000, 106, 705-712.	2.9	69
35	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 139-149.	5.6	68
36	Liver disease in adult patients with cystic fibrosis: A frequent and independent prognostic factor associated with death or lung transplantation. Journal of Hepatology, 2011, 55, 1377-1382.	3.7	64

#	Article	IF	Citations
37	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 928-940.	5.6	62
38	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Journal of Cystic Fibrosis, 2021, 20, 25-30.	0.7	62
39	The changing epidemiology and demography of cystic fibrosis. Presse Medicale, 2017, 46, e87-e95.	1.9	60
40	Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities. BioMed Research International, 2014, 2014, 1-9.	1.9	55
41	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238.	2.7	53
42	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	6.7	53
43	Prognostic value of six minute walk test in cystic fibrosis adults. Respiratory Medicine, 2013, 107, 1881-1887.	2.9	51
44	Topological data analysis reveals genotypeâ€“phenotype relationships in primary ciliary dyskinesia. European Respiratory Journal, 2021, 58, 2002359.	6.7	49
45	MUC5AC, a Gel-Forming Mucin Accumulating in Gallstone Disease, Is Overproduced via an Epidermal Growth Factor Receptor Pathway in the Human Gallbladder. American Journal of Pathology, 2006, 169, 2031-2041.	3.8	47
46	Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Archives of Disease in Childhood, 2012, 97, 960-966.	1.9	47
47	Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respiratory Research, 2006, 7, 14.	3.6	43
48	Impact of current cough on health-related quality of life in patients with COPD. International Journal of COPD, 2016, Volume 11, 2091-2097.	2.3	43
49	Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. Journal of Allergy and Clinical Immunology, 2000, 105, 739-745.	2.9	40
50	IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L67-L75.	2.9	40
51	Heme Oxygenase-1 Prevents Airway Mucus Hypersecretion Induced by Cigarette Smoke in Rodents and Humans. American Journal of Pathology, 2008, 173, 981-992.	3.8	40
52	Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?. Drugs, 2014, 74, 1073-1089.	10.9	40
53	Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 592-602.	5.6	40
54	Clinical COPD phenotypes identified by cluster analysis: validation with mortality. European Respiratory Journal, 2012, 40, 495-496.	6.7	38

#	Article	IF	Citations
55	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. European Respiratory Journal, 2017, 49, 1601873.	6.7	38
56	Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 489-496.	0.7	38
57	Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis, 2015, 14, 594-599.	0.7	37
58	Impact of gender on COPD expression in a real-life cohort. Respiratory Research, 2014, 15, 20.	3.6	35
59	Hostâ€“microbe interactions in distal airways: relevance to chronic airway diseases. European Respiratory Review, 2015, 24, 78-91.	7.1	35
60	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Journal of Cystic Fibrosis, 2021, 20, 566-577.	0.7	34
61	Chronic cough and sputum production: a clinical COPD phenotype?: Table 1â€“. European Respiratory Journal, 2012, 40, 4-6.	6.7	33
62	Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatric Pulmonology, 2017, 52, 190-197.	2.0	33
63	First Wave of COVID-19 in French Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 3624.	2.4	33
64	Targeting cytosolic proliferating cell nuclear antigen in neutrophil-dominated inflammation. Frontiers in Immunology, 2012, 3, 311.	4.8	31
65	Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?. European Respiratory Journal, 2014, 43, 1201-1203.	6.7	31
66	Employment and work disability in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 137-143.	0.7	30
67	Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. European Respiratory Journal, 2016, 48, 249-252.	6.7	30
68	Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respiratory Care, 2008, 53, 1482-9.	1.6	27
69	Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 584-586.	5.6	26
70	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
71	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.7	24
72	Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 778-781.	1.8	24

#	Article	IF	Citations
73	Association between occupational exposure and the clinical characteristics of COPD. BMC Public Health, 2012, 12, 302.	2.9	22
74	Lung immunoglobulin A immunity dysregulation in cystic fibrosis. EBioMedicine, 2020, 60, 102974.	6.1	22
75	Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. Journal of Cystic Fibrosis, 2017, 16, 85-88.	0.7	21
76	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	5.5	21
77	Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution inPseudomonas aeruginosaInfection. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 740-750.	2.9	20
78	CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. European Respiratory Journal, 2013, 42, 1553-1562.	6.7	19
79	Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. European Respiratory Journal, 2021, , 2101344.	6.7	19
80	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. International Journal of COPD, 2021, Volume 16, 321-332.	2.3	18
81	Dysfunctional lung anatomy and small airways degeneration in COPD. International Journal of COPD, 2013, 8, 7.	2.3	17
82	Arpin is critical for phagocytosis in macrophages and is targeted by human rhinovirus. EMBO Reports, 2020, 21, e47963.	4.5	17
83	CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells, 2022, 11, 1769.	4.1	17
84	Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 243.	3.9	16
85	An automated computed tomography score for the cystic fibrosis lung. European Radiology, 2018, 28, 5111-5120.	4.5	16
86	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	6.7	16
87	Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Respiratory Medicine and Research, 2021, 80, 100829.	0.6	16
88	Association of chronic nasal symptoms with dyspnoea and qualityâ€ofâ€life impairment in chronic obstructive pulmonary disease. Respirology, 2014, 19, 346-352.	2.3	15
89	Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis. European Respiratory Journal, 2017, 50, 1700763.	6.7	15
90	Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulmonary Medicine, 2019, 19, 127.	2.0	15

#	Article	IF	Citations
91	Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231.	0.7	15
92	Bronchial rupture related to endobronchial stenting in relapsing polychondritis. European Respiratory Review, 2012, 21, 367-369.	7.1	14
93	Relationship between gender and survival in a real-life cohort of patients with COPD. Respiratory Research, 2019, 20, 191.	3.6	14
94	Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. International Journal of COPD, 2021, Volume 16, 2363-2373.	2.3	14
95	Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respiratory Medicine, 2022, 200, 106921.	2.9	14
96	Pulmonary Acceleration Time to Optimize the Timing of Lung Transplant in Cystic Fibrosis. Pulmonary Circulation, 2012, 2, 75-83.	1.7	13
97	Complications of Peripherally Inserted Central Catheters in Adults with Cystic Fibrosis or Bronchiectasis. Journal of Vascular Access, 2015, 16, 245-249.	0.9	13
98	An attempt at modeling COPD epidemiological trends in France. Respiratory Research, 2018, 19, 130.	3.6	13
99	Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities . International Journal of COPD, 2019, Volume 14, 1399-1410.	2.3	13
100	Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 23-38.	2.5	13
101	COVID-19 outcomes in people with cystic fibrosis. Current Opinion in Pulmonary Medicine, 2021, 27, 538-543.	2.6	13
102	Î²2-Agonist modulates epithelial gene expression involved in the T- and B-cell chemotaxis and induces airway sensitization in human isolated bronchi. Pharmacological Research, 2010, 61, 121-128.	7.1	12
103	Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A metaâ€analysis. Pediatric Pulmonology, 2020, 55, 2653-2661.	2.0	12
104	Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respiratory Research, 2014, 15, 64.	3.6	11
105	p.Arg75Gln, a CFTR variant involved in the risk of CFTR-related disorders?. Journal of Human Genetics, 2014, 59, 206-210.	2.3	11
106	Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death. European Respiratory Journal, 2019, 53, 1801943.	6.7	11
107	Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry. Journal of Cystic Fibrosis, 2019, 18, 396-398.	0.7	11
108	DCTN4 as a modifier of chronicPseudomonas aeruginosainfection in cystic fibrosis. Clinical Respiratory Journal, 2016, 10, 777-783.	1.6	10

#	Article	IF	Citations
109	Automated computed tomographic scoring of lung disease in adults with primary ciliary dyskinesia. BMC Pulmonary Medicine, 2018, 18, 194.	2.0	10
110	Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs. Methods in Molecular Biology, 2018, 1845, 223-239.	0.9	10
111	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020.	2.6	10
112	Reply to Kuek etÂal.: Optimism with Caution: Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 372-374.	5.6	10
113	Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. European Respiratory Review, 2022, 31, 210259.	7.1	10
114	Chronic Cough in Chronic Obstructive Pulmonary Disease: Time for Listening?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 902-904.	5.6	9
115	Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2017, 17, 25.	2.0	9
116	Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis. Clinical Infectious Diseases, 2022, 75, 2135-2144.	5.8	9
117	Mediastinal Tuberculosis in an Adult Patient with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 750-751.	3.9	8
118	Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD. International Journal of COPD, 2021, Volume 16, 1275-1284.	2.3	8
119	Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge. Journal of Cystic Fibrosis, 2022, 21, 691-706.	0.7	8
120	Everolimus-related organizing pneumonia: a report establishing causality. Investigational New Drugs, 2012, 30, 1244-1247.	2.6	7
121	A first step to STOP cystic fibrosis exacerbations. Journal of Cystic Fibrosis, 2017, 16, 529-531.	0.7	7
122	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	1.6	7
123	Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada. European Respiratory Journal, 2022, 59, 2100014.	6.7	7
124	CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?. Pancreatology, 2016, 16, 515-522.	1.1	6
125	Do Cough and Sputum Production Predict COPD Exacerbations?. Chest, 2019, 156, 641-642.	0.8	6
126	Effective control ofStaphylococcus aureuslung infection despite tertiary lymphoid structure disorganisation. European Respiratory Journal, 2021, 57, 2000768.	6.7	6

#	Article	IF	Citations
127	Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 155-159.	0.7	6
128	United Airway Diseases. Should We Add Upper Airway Inflammatory Disorders to the List of Chronic Obstructive Pulmonary Disease Comorbidities?. Annals of the American Thoracic Society, 2015, 12, 968-970.	3.2	5
129	Are there specific clinical characteristics associated with physicianâ€™s treatment choices in COPD?. Respiratory Research, 2019, 20, 189.	3.6	5
130	Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?. European Respiratory Journal, 2020, 56, 2002645.	6.7	5
131	Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. BMJ Open, 2020, 10, e035811.	1.9	5
132	COVID-19 vaccine prioritisation for people with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 715-716.	0.7	5
133	Tobramycin safety and efficacy review article. Respiratory Medicine, 2022, 195, 106778.	2.9	5
134	Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 936-937.	5.6	4
135	Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. European Respiratory Journal, 2015, 45, 260-262.	6.7	4
136	Renin-associated hypertension after bronchial artery embolization in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 213-215.	0.7	4
137	Blood eosinophil counts as a guide for COPD treatment strategies. Lancet Respiratory Medicine,the, 2018, 6, 78-80.	10.7	4
138	Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis. Journal of Clinical Pathology, 2018, 71, 752-753.	2.0	4
139	Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis. Mediators of Inflammation, 2018, 2018, 1-3.	3.0	4
140	A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2018, 17, 636-642.	0.7	4
141	â€œIl faut continuer Ã poser des questionsâ€•patient reported outcome measures in cystic fibrosis: An anthropological perspective. Journal of Cystic Fibrosis, 2021, 20, e108-e113.	0.7	4
142	Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. Radiology: Cardiothoracic Imaging, 2020, 2, e200022.	2.5	4
143	Multimorbidity in Elderly Patients with Chronic Obstructive Pulmonary Disease: Stop Smoking! Go Exercise?. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 7-8.	5.6	4
144	People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study. ERJ Open Research, 2022, 8, 00686-2021.	2.6	3

#	Article	IF	Citations
145	Toward Personalized Prescription of Systemic Steroids for Patients Hospitalized With COPD Exacerbations. Chest, 2016, 150, 268-269.	0.8	2
146	On Don Quixote and pink puffers: multi-organ loss of tissue COPD. European Respiratory Journal, 2018, 51, 1702560.	6.7	2
147	Airway mucus accumulation in COPD: the cholinergic paradox!. European Respiratory Journal, 2020, 55, 1902473.	6.7	2
148	â€œCanâ€™t Stop the Feelingâ€• Symptoms as the Key to Trial Success in Bronchiectasis?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1461-1462.	5.6	2
149	Validation of short- and long-term demographic forecasts using the Canadian Cystic Fibrosis Registry. European Respiratory Journal, 2020, 55, 1901667.	6.7	2
150	Mucus Plugs in Medium-sized Airways: A Novel Imaging Biomarker for Phenotyping Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 932-934.	5.6	2
151	Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries. European Respiratory Journal, 2021, 58, 2101487.	6.7	2
152	Mucus and Mucin-Secreting Cells. , 2002, , 155-163.		2
153	Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers. Journal of Clinical and Translational Endocrinology, 2022, 28, 100298.	1.4	2
154	Cystic Fibrosis in 2021: â€œThe Times They Are A-Changinâ€• Archivos De Bronconeumologia, 2022, 58, 536-538.	0.8	1
155	Change in Lung Function after Initiation of Elexacaftorâ€“Tezacaftorâ€“Ivacaftor: Do Not Forget Anatomy!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1365-1366.	5.6	1
156	Monitoring disease progression in COPD patients: one step beyond!. European Respiratory Journal, 2014, 43, 665-667.	6.7	0
157	Cured bronchi! Extending the use of nebulised hypertonic saline outside of cystic fibrosis?. European Respiratory Journal, 2018, 51, 1800755.	6.7	0
158	Respiratory Medicine and Research: The new English-language journal of the SociÃ©tÃ© de pneumologie de langue franÃ§aise!. Respiratory Medicine and Research, 2019, 75, A1-A2.	0.6	0
159	Reply to Polverino: Deconvoluting Chronic Obstructive Pulmonary Disease: Are B Cells the Frontrunners?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1171-1172.	5.6	0
160	Management of early infection with Pseudomonas aeruginosa in adults with bronchiectasis: A survey of French pulmonologist's practices. Respiratory Medicine and Research, 2021, 80, 100859.	0.6	0
161	Modeling future COPD epidemiology. , 2016, , .		0
162	PP128 Quantifying The Relative Importance Of Chronic Obstructive Pulmonary Disease Symptoms To Patients. International Journal of Technology Assessment in Health Care, 2019, 35, 61-61.	0.5	0

#	Article	IF	Citations
163	Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging. European Respiratory Journal, 2022, , 2200022.	6.7	0
164	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. Respiratory Medicine and Research, 2022, 81, 100889.	0.6	0
165	Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?. European Respiratory Journal, 2021, , 2102924.	6.7	0
166	No patient left behind! Therapeutic options for cystic fibrosis patients living with lung transplantation. Journal of Cystic Fibrosis, 2022, , .	0.7	0